Lipase variants, polynucleotides encoding same and the use thereof

US11326152B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11326152-B2
Application numberUS-201716316458-A
CountryUS
Kind codeB2
Filing dateJul 14, 2017
Priority dateJul 18, 2016
Publication dateMay 10, 2022
Grant dateMay 10, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to lipase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

First claim

Opening claim text (preview).

The invention claimed is: 1. A lipase variant of a parent lipase, which comprises (a) a modification at a position corresponding to position 225 of the polypeptide of SEQ ID NO: 1, wherein the modification is a deletion, an insertion of Arg, or a substitution with Arg or Lys, and (b) a modification at a position corresponding to position 231 of the polypeptide of SEQ ID NO: 1, wherein the modification is a substitution with Arg, wherein the lipase variant has at least 90% sequence identity and less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 and the lipase variant has lipase activity. 2. The lipase variant of claim 1 , which has at least 95% sequence identity to the polypeptide of SEQ ID NO: 1. 3. The lipase variant of claim 1 , which has at least 97% sequence identity to the polypeptide of SEQ ID NO: 1. 4. The lipase variant of claim 1 , wherein said lipase variant further comprises one or more substitutions that correspond to substitutions in the polypeptide of SEQ ID NO: 1, selected from the group consisting of R81Q; S83T; R84H; S85T; I186L, I86P, I86V, I86W; E87A, E87I, E87K, E87T, E87V; N88Q; I90L, I90M; G91A, G91L, G91N, G91Q, G91T; N92D, N92K; L93F; N94D, N94K, N94R; F95A, F95L, F95Y; D96E, D961, D96L, D96T: L97F, L97M, L97P; K98D, K98E, K981, K98Q; and E99K. 5. The lipase variant of claim 1 , which further comprises one or more substitutions at positions corresponding to positions selected from: 27, 33, 38, 51, 56, 57, 58, 60, 69, 101, 106, 111, 131, 149, 150, 163, 198, 210, 211, 216, 220, 254, 255, 256, 263, 264, 265, 266, 267, and 269 of the polypeptide of SEQ ID NO: 1. 6. The lipase variant of claim 5 , which further comprises one or more substitutions corresponding to substitutions in the polypeptide of SEQ ID NO: 1 selected from the group consisting of: 27N, 27R; 33K, 33Q; 38A; 51I, 51L, 51V; 56K, 56Q, 56R, 56S; 57G, 57N; 58A; 60S; 69R; 101R; 106K, 106R; 111A; 131T; 149D; 150G; 163K, 163S; 198S; 210K, 210Q; 211L; 216P; 220F; 254S; 255A, 255T; 256K, 256T, 256V; 263Q; 264A, 264F, 264W; 265T; 266D; 267A; and 269N. 7. The lipase variant of claim 1 , wherein said variant comprises one-set of modifications that correspond to modifications in the polypeptide of SEQ ID NO: 1 selected from the group consisting of: N200R + G225R, S224K + G225K, S224K + G225K + L227K, S224R + G225R, S224R + G225R + L227R + V228*, S224* + G225* + T226R + L227R + V228*, S224* + G225* + T226* + L227R + V228R + V230*, S224* + G225* + T226* + L227R + P229R, G225GR, G225R + T226R, G225R + L227R, G225R + V228R, G225R + P229R, G225R + T231R, G225R + N233R, and G225* + T226* + L227R + V228R. 8. The lipase variant of claim 1 , wherein said variant has improved wash performance, a higher Benefit Risk Factor (BRF), higher relative wash performance (RP(Wash)) or lower relative odor (RP(Odor)) compared to the lipase of SEQ ID NO: 1. 9. A composition comprising the lipase variant of claim 1 and a surfactant. 10. The lipase variant of claim 1 , wherein said variant comprises a deletion or an insertion of Arg at the position corresponding to position 225 of the polypeptide of SEQ ID NO: 1. 11. The lipase variant of claim 1 , wherein said variant comprises modifications that correspond to modifications G225R+T231R in the polypeptide of SEQ ID NO: 1. 12. A method for cleaning a surface, comprising contacting the surface with the lipase variant of claim 1 . 13. A method of hydrolyzing a lipase substrate, comprising treating the lipase substrate with the lipase variant of claim 1 .

Assignees

Inventors

Classifications

  • containing lipase · CPC title

  • Triacylglycerol lipase (3.1.1.3) · CPC title

  • C12N9/20Primary

    Triglyceride splitting, e.g. by means of lipase · CPC title

  • Carboxylic ester hydrolases {(3.1.1)} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11326152B2 cover?
The present invention relates to lipase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
Who is the assignee on this patent?
Novozymes As
What technology area does this patent fall under?
Primary CPC classification C12N9/20. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).